COST-EFFECTIVENESS ANALYSIS OF DIRECTLY OBSERVED THERAPY FOR TUBERCULOSIS AND ITS EXPANSION IN RIO DE JANEIRO

ANA CAROLINA MACHADO RUSSO DE MOURA1, GABRIELA BITTENCOURT GONZALEZ MOSEGUI1, CID MANSO DE MELLO VIANNA2, BENEDITO CARLOS CORDEIRO1

1Professional Master’s Degree in Pharmaceutical Care Management, Fluminense Federal University (Universidade Federal Fluminense–UFF), Brazil, 2Social Medicine Institute (Instituto de Medicina Social), Rio de Janeiro State University, Brazil

Email: gabriela.mosegui@uol.com.br

ABSTRACT

Objective: Brazil is one of the countries with the largest number of cases of tuberculosis worldwide. Rio de Janeiro exhibits some of highest mortality and incidence rates in the country. The aim of the present study was to perform a cost-effectiveness analysis of directly observed therapy (DOT) and simulate its expansion for new cases of pulmonary tuberculosis in Rio de Janeiro.

Methods: A decision tree was plotted that simulated the progression of the disease for six months. In the cost-effectiveness analysis, strategies of self-administered treatment (SAT) and DOT (directly observed therapy) with 100% coverage were compared; the current coverage, 48%, and coverage of 100% were considered with regard to expansion. The study was based on the epidemiological pattern of tuberculosis in Rio de Janeiro among adults from both genders and without economic differences; the government perspective was adopted. The outcomes were varied to investigate the occurrence of parametric sensitivity.

Results: Although the cost of treatment was increased by three times, DOT proved to be cost-effective for the treatment of new cases, with an incremental cost-effectiveness ratio (ICER) of BRL 30,454 per saved life. Expansion of DOT coverage would avert 180 deaths and 171 instances of treatment dropout, in addition to providing an incremental 420 instances of cure, with an investment of approximately BRL 6,700,000.00.

Conclusion: DOT might contribute to improving the current tuberculosis situation in the state of Rio de Janeiro. Its expansion would fit with the resources estimated by the Brazilian government needed to combat non-drug-resistant tuberculosis.

Keywords: Tuberculosis, Directly Observed Therapy, DOT, Cost-Effectiveness Analysis, Healthcare Assessment

INTRODUCTION

Tuberculosis is a re-emerging disease that represents a serious public health problem. Despite antibiotic therapy and the formulation of specific policies for treatment, control and prevention, tuberculosis was the main cause of death due to infectious diseases worldwide in 2014 [1]. Brazil is among the 22 countries that account for 80% of cases, and the state of Rio de Janeiro exhibits one of the worst scenarios in the country, with the highest mortality rate and the second highest incidence in 2014 [1, 2].

Treatment dropout with consequent worsening of the disease is one of the main factors responsible for the current situation. To improve this condition, the tuberculosis control strategy recommended by the World Health Organization (WHO) is the directly observed therapy (DOT). DOT means that a trained health care worker or other designated individual (excluding a family member) provides the prescribed TB drugs and watches the patient swallow every dose [3]. Although DOT is to guarantee the commitment of patients, healthcare professionals and the government to treatment [1], the real effectiveness is determined by many complex factors [4, 5]. In 2014, the coverage of DOT for new cases of tuberculosis in the state of Rio de Janeiro was 48% [6]; expansion of DOT coverage is expected to improve the disease indexes via an increase in the cure rate and a reduction of dropouts and deaths.

Even if DOTS regimen is well studied and globally accepted treatment method, in not all countries the treatment shown be cost-effective [7]. As the financial burden for implementation of 100% program is high, the decision is not trivial, nevertheless WHO recommendation. The aims of the present study were to develop a decision-tree model for the cost-effectiveness analysis of DOT for new cases of tuberculosis in Rio de Janeiro and to perform a budget impact analysis of the expansion of DOT coverage for this Brazilian state.

MATERIALS AND METHODS

A decision tree model was plotted to simulate the stages of tuberculosis treatment for cost-effectiveness analysis of DOT for six months of treatment of 10,000 new cases, considering patients with a weight over 50 kg and without drug resistance from the state of Rio de Janeiro. The following interventions were compared: (a) self-administered treatment (SAT), in which patients take their medicines at home and visit a healthcare unit once per month for medical assessment and to receive the medicines, and (b) DOT, in which patients visit a healthcare unit at least three times per week to take their medicines under the supervision of a healthcare professional. In the budget impact analysis, the strategies of (a) DOT with 48% of coverage of pulmonary tuberculosis cases and (b) DOT with 100% of coverage were compared.

For the cost-effectiveness analysis, a decision tree was plotted using Tree Age software [8]. The data used in the model were extracted from databases and cost-effectiveness studies [9, 10]. Health states represent the forms of progression of infection. All individuals included in the cohort were patients diagnosed with active pulmonary disease without drug resistance. After six months of treatment with the basic regimen, five outcomes were considered: (a) treatment success; (b) treatment failure; (c) treatment dropout; (d) death due to tuberculosis-related complications; and (e) deaths due to other causes.
The following assumptions were considered in the construction of the decision model: (a) the patients included were diagnosed with active tuberculosis without resistance to any anti-tuberculosis drug; (b) a higher adherence to treatment would result in a larger number of individuals cured and a lower dropout rate; (c) cases of spontaneous cure following treatment dropout were not considered; (d) non-notified cases, false-negative cases and diagnosed patients who had not started treatment were not considered; (e) the cost of implantation and management of DOT at healthcare units was not considered; and (f) direct medical costs related to medicines, human resources and testing for tuberculosis treatment were considered.

**Probabilities**

Probabilities were estimated based on epidemiological data provided by the Health Ministry [2-5, 11-12]. Average percentages for the period of 2007-2014 were calculated for the following outcomes: treatment dropout, death due to tuberculosis and death due to other causes (table 1). These percentages were considered as probabilities, and the same value was used for the treatment failure outcome, as it is not associated with the DOT and SAT strategies [9].

The variable treatment time (TT), namely, the average number of months of treatment over the six-month period, was used to calculate the cost of medicines, testing and human resources. For the cure and treatment failure outcomes, the time corresponded to the full time period of the basic regimen.

**Costs**

The unified health system (Sistema Único de Saúde-SUS) perspective was adopted for the analysis. The direct medical costs considered were divided into three categories: medicines, human resources involved in the care of tuberculosis patients with or without DOT and post-diagnosis tests.

The medicines employed in each regimen and the treatment time recommended in the protocol established by the Health Ministry were used in the calculations [11]. All values were obtained through request via the Health Ministry information access site [13].

According to the treatment protocol for new cases of tuberculosis established by the Health Ministry, a six-month course of treatment with the basic regimen resulted in a cost of BRL 155.28 for medicines (table 2).

The variable treatment time (TT), namely, the average number of months of treatment over the six-month period, was used to calculate the cost of medicines, testing and human resources. For the cure and treatment failure outcomes, the time corresponded to the full time period of the basic regimen.

**Table 1: Probabilities and treatment time of outcomes for tuberculosis with and without DOT**

<table>
<thead>
<tr>
<th>Probabilities</th>
<th>SAT (%)</th>
<th>TT (months)</th>
<th>DOT (%)</th>
<th>TT (months)</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cure</td>
<td>6</td>
<td>6</td>
<td>-</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Dropout</td>
<td>16</td>
<td>4</td>
<td>14</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Death due to tuberculosis</td>
<td>4.2</td>
<td>3</td>
<td>2.4</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Death due to other causes</td>
<td>2.8</td>
<td>3</td>
<td>2.1</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Failure</td>
<td>2</td>
<td>6</td>
<td>2</td>
<td>6</td>
<td>6</td>
</tr>
</tbody>
</table>

DOT: directly observed therapy; SAT: self-administered treatment; TT: treatment time in months

**Table 2: Cost of medicines for 6 mo of treatment with the basic regimen**

<table>
<thead>
<tr>
<th>Medicines/ dose</th>
<th>Unit value (BRL)</th>
<th>Tablets/day</th>
<th>TT (days)</th>
<th>Medicines total cost</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>RHZE (150/75/400/275 mg)</td>
<td>0.3816</td>
<td>4</td>
<td>60</td>
<td>91.584</td>
<td>[9]</td>
</tr>
<tr>
<td>RH (150/100 mg)</td>
<td>0.1327</td>
<td>4</td>
<td>120</td>
<td>63.696</td>
<td>[9]</td>
</tr>
<tr>
<td>Total cost of treatment</td>
<td>-</td>
<td>-</td>
<td>180</td>
<td>155.28</td>
<td>-</td>
</tr>
</tbody>
</table>

RHZE: rifampicin, isoniazid, pyrazinamide and ethambutol; RH: rifampicin and isoniazid; TT: treatment time

Both the approach and the cost of human resources were considered based on data from public health care units in Rio de Janeiro, as in the studies by Steffen et al. (2010) and Mohan et al. (2007) [10, 14]. As tuberculosis treatment and DOT supervision occur within the opening hours of the health basic units, DOT does not involve additional costs related to structure, only those related to human resources. The salary of the professionals charged with medical care and observation of medicine intake, i.e., nurses or nursing technicians, was considered in the estimation of the relationship between time spent by employees in the analysed activity and the resources spent. In the present study, supervision was performed five times per week for two months and three times per week for four months, resulting in a total of approximately 88 incidences of supervised medicine intake [10, 14]. Following salary readjustment according to the table for municipal employees in Rio de Janeiro [15-20], the cost was BRL 481.04 and BRL 1,847.82 for SAT and DOT, respectively.
The cost of post-diagnostic testing was obtained from the SUS System of Management from the table for Procedures, Medicines and OPM (orthoses, prostheses and materials) [13]. In the basic regimen, for cases of pulmonary tuberculosis, the Health Ministry recommends bacilloscopy of sputum once per month. The cured patients thus underwent sputum bacilloscopy six times, with a cost of BRL 25.20. In addition, patients who experienced treatment failure were also subjected to investigation for acid-fast bacilli (AFB) and an antibiogram for mycobacteria, with a total expense of testing of BRL 44.16.

The resources allocated per patient represent the total sum of expenses for medicines, human resources and testing. Patients cured after treatment with the basic regimen consumed resources for a period of six months; the cost of treatment when SAT was applied was BRL 662.00, and the cost with DOT was BRL 2.028.00. Therefore, the patients subjected to DOT required three times more resources than those treated with SAT.

**Effectiveness**

Broadening of the scope of DOT coverage is intended to reduce the mortality rate of tuberculosis, i.e., to reduce the number of deaths caused by the disease due to lack of treatment. This outcome was measured as the number of lives saved, corresponding to patients cured as a result of the adopted strategy [21-23].

**Budget impact**

The budget impact analysis was performed by considering a broadened coverage of DOT for new cases of pulmonary tuberculosis without drug resistance. The coverage was thus increased from 48%, i.e., the scope in 2014, to 100%, which is the ideal goal established by the National Programme of Tuberculosis Control (Programa Nacional de Controle da Tuberculose) for high-priority municipalities [24].

**RESULTS**

**Effectiveness**

The effectiveness of tuberculosis treatment was measured as the number of cured patients. Simulation of DOT for 100% of a cohort composed of 10,000 new cases of tuberculosis without drug resistance subjected to the six-month basic regimen resulted in 180 fewer deaths than that of SAT and 22 fewer deaths than the current DOT coverage, 48%. In addition, DOT with 100% coverage resulted in an additional 420 instances of cure compared to SAT and 218 additional instances of cure compared to SAT with 48% coverage. One additional benefit was 171 fewer cases of treatment dropout. These values are comparable to those obtained in studies conducted in Belém, Pará state, Brazil, and in Peru [23,25].

**Cost-effectiveness analysis**

DOT with the current coverage is preferable to DOT with 100% coverage, as the incremental cost-effectiveness ratio (ICER), BRL 30,454 per cured patient in Rio de Janeiro relative to new cases of tuberculosis without drug resistance, was similar in both cases. Therefore, this situation is preferable to any proportional combination of DOT and SAT. Table 3 describes the values obtained in the simulation.

<table>
<thead>
<tr>
<th>Strategy</th>
<th>Cost (R$)</th>
<th>Effectiveness (cured patients)</th>
<th>IC (R$)</th>
<th>IE(cured patients)</th>
<th>ICER (BRL/cured patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAT</td>
<td>6,280,486.00</td>
<td>7,533</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DOT (100%)</td>
<td>19,088,200.00</td>
<td>7,953</td>
<td></td>
<td>12,797,723.00</td>
<td>420</td>
</tr>
</tbody>
</table>

SAT—self-administered treatment; DOT—directly observed therapy; IC—incremental cost; IE—incremental effectiveness; ICER—incremental cost-effectiveness ratio

**Sensitivity analysis**

To determine which variables exerted a greater impact on the results obtained, a tornado diagram was plotted for the first decision tree model of total costs (fig. 2). The costs of medicines (rifampicin, isoniazid, pyrazinamide and ethambutol (RHZE) and rifampicin and isoniazid (RH)) were increased or decreased by 20%, along with the costs of sputum bacilloscopy and the human resources expenses involved in DOT. Human resources were practically the only factor that accounted for the variation of costs, but it did not significantly impact the final result.

**DISCUSSION**

Two studies that conducted a cost-effectiveness analysis of DOT performed in healthcare units in Rio de Janeiro rated DOT as a cost-
The analysis performed showed that supervised therapy might be a cost-effective strategy for the treatment of new cases of pulmonary tuberculosis in the state of Rio de Janeiro. However, expansion of DOT coverage might not suffice to attain the goals of an 85% cure with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), or to other healthcare systems based on reimbursement or payment.

CONCLUSION

The analysis performed showed that supervised therapy might be a cost-effective strategy for the treatment of new cases of drug-resistant tuberculosis in the current 48% to 100%, the government of the state of Rio de Janeiro must spend approximately BRL 6,700,000.00 (USD 1,90,000.00). This amount represents 3% of that spent in 2015 (USD 65,000,000.00) in Brazil for non-drug-resistant tuberculosis and 4% of the resources (USD 47,000,000.00) that the government needs to invest to combat non-drug-resistant tuberculosis [1]. Considering that Rio de Janeiro accounted for 15% of the new cases of tuberculosis in Brazil in 2012 [2], such an investment might be considered by health managers.

The main limitations of the present study derive from the fact that it did not consider the secondary benefits of treatment, such as reduction of transmissibility, or the instances of relapse and retreatment. In addition, the data for probabilities were procured from governmental databases, which may be subject to distortion related to the quality of information, underreporting or duplicate records.

In addition, because the perspective of the health system was adopted, the costs for patients and their relatives were not considered. Both the structural costs associated with DOT implantation and training of the involved professionals nor the costs of other medications also used, especially in severe and drug-resistant cases, were considered.

Finally, the results of the present study cannot be extrapolated to other, more narrowly-focused populations, e.g., patients infected with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS), or to other healthcare systems based on reimbursement or payment.


How to cite this article